CSBR
Price
$7.11
Change
-$0.07 (-0.97%)
Updated
Jan 15, 10:58 AM (EDT)
Capitalization
99.7M
61 days until earnings call
Intraday BUY SELL Signals
MREO
Price
$0.69
Change
-$0.03 (-4.17%)
Updated
Jan 15, 11:51 AM (EDT)
Capitalization
114.03M
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CSBR vs MREO

Header iconCSBR vs MREO Comparison
Open Charts CSBR vs MREOBanner chart's image
Champions Oncology
Price$7.11
Change-$0.07 (-0.97%)
Volume$200
Capitalization99.7M
Mereo BioPharma Group
Price$0.69
Change-$0.03 (-4.17%)
Volume$15.35K
Capitalization114.03M
CSBR vs MREO Comparison Chart in %
CSBR
Daily Signal:
Gain/Loss:
MREO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CSBR vs. MREO commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Hold and MREO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CSBR: $7.18 vs. MREO: $0.72)
Brand notoriety: CSBR and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 38% vs. MREO: 165%
Market capitalization -- CSBR: $99.7M vs. MREO: $114.03M
CSBR [@Biotechnology] is valued at $99.7M. MREO’s [@Biotechnology] market capitalization is $114.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 2 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CSBR’s FA Score: 2 green, 3 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, CSBR is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 6 TA indicator(s) are bullish while MREO’s TA Score has 5 bullish TA indicator(s).

  • CSBR’s TA Score: 6 bullish, 4 bearish.
  • MREO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CSBR is a better buy in the short-term than MREO.

Price Growth

CSBR (@Biotechnology) experienced а +6.37% price change this week, while MREO (@Biotechnology) price change was +69.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.23%. For the same industry, the average monthly price growth was +2.54%, and the average quarterly price growth was +43.40%.

Reported Earning Dates

CSBR is expected to report earnings on Mar 17, 2026.

MREO is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Biotechnology (-0.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MREO($114M) has a higher market cap than CSBR($99.7M). MREO YTD gains are higher at: 71.970 vs. CSBR (3.907). CSBR has higher annual earnings (EBITDA): 4.56M vs. MREO (-40.14M). MREO has more cash in the bank: 48.7M vs. CSBR (10.3M). MREO has less debt than CSBR: MREO (397K) vs CSBR (5.75M). CSBR has higher revenues than MREO: CSBR (56.9M) vs MREO (500K).
CSBRMREOCSBR / MREO
Capitalization99.7M114M87%
EBITDA4.56M-40.14M-11%
Gain YTD3.90771.9705%
P/E Ratio42.24N/A-
Revenue56.9M500K11,380%
Total Cash10.3M48.7M21%
Total Debt5.75M397K1,448%
FUNDAMENTALS RATINGS
CSBR vs MREO: Fundamental Ratings
CSBR
MREO
OUTLOOK RATING
1..100
8322
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1198
PRICE GROWTH RATING
1..100
5998
P/E GROWTH RATING
1..100
92
SEASONALITY SCORE
1..100
5045

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (63) in the null industry is in the same range as CSBR (85) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

MREO's Profit vs Risk Rating (100) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for MREO (98) in the null industry. This means that CSBR’s stock grew significantly faster than MREO’s over the last 12 months.

CSBR's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for MREO (98) in the null industry. This means that CSBR’s stock grew somewhat faster than MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is in the same range as CSBR (9) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRMREO
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 30 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signal:
Gain/Loss:
MREO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TAAG0.04N/A
N/A
The Awareness Group
CZNL51.99N/A
N/A
Citizens National Corp.
IHCPF9.80N/A
N/A
Inchcape PLC
NCCGF1.86N/A
N/A
NCC Group Plc, Manchester
SARTF225.00N/A
N/A
Sartorius AG

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+1.77%
SYRE - CSBR
32%
Poorly correlated
+5.17%
SCNI - CSBR
27%
Poorly correlated
+15.59%
PHAT - CSBR
26%
Poorly correlated
-3.13%
OABI - CSBR
25%
Poorly correlated
+0.53%
MREO - CSBR
24%
Poorly correlated
+8.58%
More

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been closely correlated with RARE. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+8.58%
RARE - MREO
84%
Closely correlated
-0.17%
TRDA - MREO
41%
Loosely correlated
+1.15%
XNCR - MREO
39%
Loosely correlated
+3.66%
SYRE - MREO
39%
Loosely correlated
+5.17%
NRIX - MREO
38%
Loosely correlated
+0.58%
More